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1 |  INTRODUCTION
Intraoral localized methotrexate-associated lymphoprolifer-
ative disorders (MTX-LPD) may be associated with antire-
sorptive agent-related osteonecrosis of the jaw (ARONJ), 
especially with purulent discharge. In patients who are on 
oral MTX and have oral ulcers, it is important to perform 
biopsy, even if they meet the diagnostic criteria for ARONJ.
Methotrexate (MTX) is the first-line treatment for rheu-
matoid arthritis (RA), as it has superior bone destruction 
suppressant effect.1 However, there are many reports on the 
adverse effects of MTX therapy. Several recent case stud-
ies reported that long-term MTX therapy resulted in MTX-
related lymphoproliferative disorder (MTX-LPD) in RA 
patients.2,3
The World Health Organization categorizes MTX-LPD as 
an “other iatrogenic immunodeficiency-associated LPD” in 
the classification of Tumors of Hematopoietic and Lymphoid 
Tissues.4 Immunosuppression by MTX is thought to re-
duce the host immunosurveillance of the Epstein-Barr virus 
(EBV)-infected B cells, as approximately 50% of MTX-LPD 
patients were EBV positive,5,6 and lead to MTX-LPD.
Antiresorptive agents, such as bisphosphonates 
(BPs) and denosumab, are the primary treatment agents 
for osteoporosis, bone metastasis, and hypercalcemia. 
Antiresorptive agents have many benefits for patients with 
skeletal complications. The use of corticosteroid and MTX 
is important for immunosuppression in RA treatment, and 
antiresorptive agents are important to prevent steroidal os-
teoporosis. In proportion to their use, cases of antiresorp-
tive agent-related osteonecrosis of the jaw (ARONJ) have 
been increasing.7 The major clinical symptoms of ARONJ 
are progressive destruction of the jaw, prolonged pain, 
bone exposure, soft tissue swelling, fistula, and infections. 
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Most of those symptoms are intractable, and many severe 
cases have been reported.8-10 Therefore, the diagnosis and 
treatment of ARONJ should be made early.
Here, we report a case of MTX-LPD in an elderly woman 
who had concurrent exposure of the maxilla, mucosal necro-
sis, and persistent pain from ARONJ caused by long-term 
denosumab to treat steroidal osteoporosis of RA. In addi-
tion, we performed a literature review to identify all cases 
of intraoral localized MTX-LPD with bone exposure and to 
investigate the characteristics and prognoses of these cases.
2 |  CASE REPORT
Patient: A 75-year-old woman.
Chief complaint: Persistent pain in the right maxillary 
mucosa and bone exposure.
Medical history: The patient had RA, osteoporosis, renal 
cancer, and schizophrenia. She had been taking 8 mg of MTX 
per week since 1998. Further, she was given denosumab for 
osteoporosis from 2013 to January 2018 (60 mg subcutane-
ously once every 6 months; the total dose administered was 
600  mg). She underwent left nephrectomy for renal can-
cer in June 2017. She was undergoing medical therapy for 
schizophrenia.
Family history: No relevant family history.
Clinical procedures and outcomes: At her first visit to 
a dentist with pain in the right maxillary mucosa in early 
February 2018, the dentist suspected ARONJ because of 
maxillary posterior bone exposure, infection, and pain. She 
visited our department for further examination and treat-
ment of the right maxillary lesion that was causing her pain 
in mid-February 2018. Her dental treatment and tooth ex-
traction history were unknown.
2.1 | Presenting symptoms
General condition: The physical constitution was slightly 
obese. Oral intake of food was impaired because of severe 
intraoral pain.
Facial condition: The countenance was symmetric. The 
cervical lymph nodes were not swollen.
Oral condition: There were jaw bone exposure, mucosal 
necrosis, and infection from the right maxillary incisors to 
the molars. The lesion gave her severe pain (Figure 1A). The 
right maxillary canine and lateral incisor were loose, suggest-
ing moderate to severe periodontitis.
Image findings: Computed tomography (CT) and mag-
netic resonance imaging (MRI) revealed osteosclerosis in the 
right maxillary jaw bone, and the upper right maxillary sinus 
mucosa was hypertrophic, suggesting acute osteomyelitis 
(Figure 1B and C).
Blood test findings: White blood cell count, 5100/μL; 
C-reactive protein, 1.35 mg/dL; creatinine, 1.04 mg/dL; es-
timated glomerular filtration rate, 20%. It suggested slight 
inflammation and renal function impairment.
We performed cytodiagnosis and biopsy at the right 
maxillary mucosa on the first medical examination day. 
She was diagnosed negative for intraepithelial lesion and 
malignancy on cytodiagnosis with granulation tissue on 
histopathology.
Clinical diagnosis: ARONJ.
We initiated treatment for ARONJ, based on the treat-
ment strategies in previous papers,11 with oral amoxicillin 
F I G U R E  1  Oral cavity at the initial examination. A, Large 
ulceration with no peripheral induration, infection with purulent 
discharge, and exposed bone in the ulcer were noted on the right 
maxillary gingiva. B and C, Computed tomography and magnetic 
resonance imaging showed osteosclerosis in the right maxillary jaw 
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(750 mg/d), oral clarithromycin (400 mg/d), and the use of 
gargle for infection control.
On hospital day 18, the inflammatory findings had un-
dergone remission (Figure 2A). However, on hospital day 
65, the maxillary jaw bone exposure and mucosal necrosis 
were found to have spread (Figure 2B). Therefore, we sus-
pected MTX-LPD because of the long-term administration 
history and rise in blood concentration of MTX because 
of renal function impairment after nephrectomy. Therefore, 
we performed re-biopsy at the right maxillary mucosa. 
On hospital day 72, we diagnosed MTX-LPD using sev-
eral immune-histological examinations. Histopathological 
examination with hematoxylin and eosin staining revealed 
severe inflammatory cell infiltration in the submucosal 
area. Granulation tissue in the deep subepithelial region 
showed Reed-Sternberg-like cells and Hodgkin cell-like 
cells. Immunohistochemical staining revealed several large 
CD20- and CD30-positive cells, which were positive for 
EBER-ISH (Figure 3).
We consulted the Department of Hematology and 
Rheumatology in our hospital to look for more lesions and 
also to replace MTX with other agents for RA. The malignant 
lymphoma tumor marker test showed that lactate dehydroge-
nase (277 IU/L) and soluble interleukin-2 receptor (862 U/
mL) were slightly elevated, but there were no findings of 
lymphoid nodal lesions on contrast-enhanced CT. Finally, 
she was diagnosed with intraoral localized MTX-LPD with 
ARONJ.
Final diagnosis: MTX-LPD (intraoral localized type) with 
ARONJ stage 2, which is characterized by exposure/necrosis 
associated with pain, infection, and fistula, in which bone is 
palpable with a probe.
On hospital day 72, in consultation with the Department 
of Hematology and Rheumatology, MTX was switched to 
salazosulfapyridine.
On hospital day 85, she was hospitalized because of poor 
pain control and difficulty in oral intake of food. We started 
9 g/d of sulbactam/ampicillin (SBT/ABPC) with topical an-
tibacterial drug (bacitracin, fradiomycin sulfate) delivery 
using a splint (Figure 4A) and professional oral management 
and gargling for acute infection from ARONJ. On hospital 
day 90, the acute symptoms had resolved. We extracted the 
mobile right canine and performed saucerization with expo-
sure of the maxillary bone. The exposed bone had undergone 
epithelization and protraction, and pain was under remission. 
On hospital day 111, she was discharged (Figure 4B).
However, on day 115, she was re-hospitalized because 
of fever, fatigue, infection of the right maxillary lesion, and 
difficulty in oral intake of food (Figure  4C). Her schizo-
phrenia caused poor compliance to instructions, and there-
fore, she had not taken some prescribed drugs. We started 
her on SBT/ABPC again. However, the result of re-culture 
of the lesion was persistent, so we switched to SBT/ABPC 
to 1.2 g/d of clindamycin phosphate. After acute symptoms 
were relieved, we extracted the mobile right lateral incisor 
and performed re-saucerization with a sharp-edged maxil-
lary bone, and the open wound was covered with a dermis 
defect graft (Terudermis®) (Figure 4D). The exposure bone 
underwent complete epithelization on hospital day 148, and 
we prescribed a dosage of antibiotics (Figure 4E).
We fabricated the denture combined with a protection 
plate, which was good for oral intake of food (Figure 4F). On 
hospital day 160, she was discharged. There was no recur-
rence of MTX-LPD or ARONJ, and RA remained well-con-
trolled. She undergoes regular follow-ups every 3-6 months.
3 |  DISCUSSION
Clinically, MTX-LPD is similar to lymphoma in patients with-
out immunodeficiency. However, both the immunological ab-
normalities of RA and the immunosuppressive effects of MTX 
F I G U R E  2  Oral findings after the initial treatment. A, 
Inflammatory findings had undergone remission on hospital day 18 
after antimicrobial administration. B, The maxillary jaw bone exposure 
and mucosal necrosis had re-spread on hospital day 65
(A)
(B)
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are considered to be involved in the pathogenesis of MTX-
LPD. In RA, specific clonal autoreactive T cells are seen, and 
in their presence, B cells that produce autoantibodies such as 
rheumatoid factor are activated. Furthermore, it has been sug-
gested that the immunosuppressive effects of MTX may cause 
viral infections or reactivation of latent viral infections and also 
induce abnormal cell proliferation.712 Among viral infections, 
EBV is considered to be more common and is thought to cause 
lymphoma by direct viral activity that spreads and propagates 
the virus from latently infected cells.13,14
Diffuse large B-cell lymphoma (DLBCL) accounts for 
approximately half of all MTX-LPD histological types, fol-
lowed by Hodgkin lymphoma (HL) at 10%-20%.15 Other 
studies have also mentioned follicular lymphoma and T-cell 
lymphoma.16 Since these are not monoclonal lesions, it is 
necessary to make a comprehensive diagnosis by combining 
immunohistochemical staining and clinical features.
In this case as well, HE staining revealed Reed-Sternberg-
like cells and Hodgkin cell-like cells in the granulation tissue. 
Immunohistological staining revealed numerous CD20/30-
positive atypical large cells, which were EBER-ISH positive. 
Since MTX was administered for a long duration of 20 years 
and the total dose was approximately 7680 mg, it was consid-
ered that immunosuppression and the proliferation of EBV-
infected cells occurred.
MTX-LPD may resolve in several weeks after withdrawal 
of the MTX therapy.17 However, additional treatments, such 
as chemotherapy and radiotherapy, should be considered 
for patients with persistent LPD after MTX withdrawal.18 
Therefore, definitive diagnostic criteria are lacking, and a 
definitive diagnosis of MTX-LPD remains challenging. As 
in this case, if there are no lymph node lesions, and the di-
agnostic criteria for ONJ are met, there is a possibility of the 
misdiagnosis of ARONJ. Therefore, in cases of oral MTX 
administration, oral surgeons should bear in mind that inci-
sional biopsy and immune-histological examination are re-
quired for the final diagnosis.
Regarding the administration of antiresorptives to patients 
under ARONJ treatment, it is reported that their discontin-
uation may be recommended until ARONJ treatments are 
completed for patients with osteoporosis, excluding those 
with high fracture risk.11 Since this case was considered to 
be an advanced complication of MTX-LPD and ARONJ, we 
F I G U R E  3  Histopathological and immunohistochemical findings. 
A, Histopathological staining with hematoxylin and eosin (×400) 
revealed severe inflammatory cell infiltration in the submucosal area. 
Granulation tissue in the deep subepithelial region, Reed-Sternberg-
like cells (Red arrow), and Hodgkin cell-like cells (Black arrow) were 
found in the granulation tissue. B-D, Immune-histological findings 
revealed many large CD20 (×400) (B) and CD30 (×400) (C)-positive 
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consulted with the department of internal medicine and de-
termined that the risk of fractures was not high. Therefore, 
we decided to withhold the antiresorptives after ARONJ 
treatment. In order to balance the risk of ARONJ and frac-
tures, it was considered necessary to determine the discontin-
uation of antiresorptives after consultation with the medical 
department.
A review of the literature revealed 22 cases of intra-
oral localized MTX-LPD with bone exposure, including 
our case (Table  1).2,3,19-35 The mean age of the patients 
was 73 years (range, 44-92 years), and the male to female 
ratio was 2:1. The mean duration of MTX treatment was 
8.6 years (range, 0.6-20 years). The frequency of DLBCL 
was 84% (16/19 cases); the frequency of EBV infection 
was 95% (19/20 cases); MTX-LPD resolved in 89% (16/18 
cases) of patients after discontinuation of MTX. Data on 
the mean age, sex ratio, duration of MTX treatment, and 
frequency of EBV infection were similar to those of previ-
ous reports on intraoral localized MTX-LPD.35 In contrast, 
the frequency of DLBCL was higher in comparison with 
previous reports on intraoral localized MTX-LPD. Intraoral 
localized MTX-LPD was considered to show good progno-
sis after drug withdrawal, with or without bone exposure. 
In three cases of no remission after withdrawal of MTX, 
chemotherapy was performed.2,23,30 Two of the three cases 
showed systemic symptoms,2,23 and in one case, a fistula 
was detected in the palatal opening in the naso-genian re-
gion.30 It was considered that the presence of extraoral 
symptoms had an influence on the prognosis of intraoral 
localized MTX-LPD.
Most intraoral localized MTX-LPD patients (20/22) were 
Japanese.3,20-30,33,35 However, the reason is unclear. Therefore, 
a study has been initiated jointly by three academic societies 
(Japan College of Rheumatology, The Japanese Society of 
Hematology, The Japanese Society of Pathology) in Japan.
In this case, it was necessary to administer antimicro-
bials during hospitalization because of evacuation in the 
exposed bone, fever, fatigue, elevation of the inflammatory 
markers, and an eating disorder caused by pain. Although 
symptom relief was observed after MTX withdrawal, bone 
exposure was continued, and reinfection of the bone ex-
posed area was observed because of interruption of the 
F I G U R E  4  Treatment course 
after hospitalization. A, In addition 
to antimicrobial drip infusion, topical 
antibacterial drug (bacitracin, fradiomycin 
sulfate) delivery using a splint was started 
on hospital day 85. B, Exposed bone had 
undergone epithelization and protraction, 
and pain was under remission on hospital 
day 90. C, The right maxillary lesion with 
infection at the time of re-hospitalization 
on day 115. D, Extraction of the mobile 
right lateral incisor and re-saucerization 
with sharp-edged maxillary bone were 
performed, and the open wound was covered 
with dermis defect grafting (Terudermis®) 
after acute symptomatic relief. E, The 
exposed bone underwent complete 
epithelization on hospital day 148. F, A 
denture combined with a protection plate 
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1 Kalantzis et al12 72, F U. gingiva Ulceration
Bone exposure
UK Polyclonal B-cell 
lesion
+ − UK − − + − −
2 Acero et al2 79, F U. gingiva Pain
Ulceration
Bone exposure
− DLBCL + − 15 y + − + + −




− DLBCL + − UK − − + − −
4 Hatanaka et al13,a 66, F U. gingiva Pain
Ulceration
Bone exposure
− DLBCL + − 12 y + + + − −
5 Yamashita et al14,a 66, F U. gingiva Pain
Bone exposure
Unhealed tooth socket
− DLBCL + 4 y 12 y − + + − −
6 Sano et al15,a 70, M U and L. gingiva Pain
Ulceration
Bone exposure
− DLBCL + − 0.4 y − + + − −
7 Minami et al16,a 60, F L. gingiva Pain
Swelling
Bone exposure
− UK + 3 y 2 y − + + + +
8 Kimoto et al17,a 64, F U and L. gingiva Pain
Ulceration
Bone exposure
− DLBCL + 2 y 3 y − + + − −
9 Aiko and 
Michiwaki 
201318,a 




− DLBCL + − 1.6 y − + + − −





Polymorphic LPD + − 10 y − − + − −
11 Horie et al20,a 60, M U. gingiva Ulceration
Bone exposure
Unhealed tooth socket
− DLBCL + − 12 y − + + − −
12 Yagihara et al21,a 87, M U. gingiva Ulceration
Bone exposure
− T-cell dominant 
polymorphic LPD
− 5 y 12 y − + + − −
13 Obata et al22,a 80, M U. gingiva Pain
Ulceration
Bone exposure
− DLBCL + − 6.3 y − − + − −
14 Saito et al23,a 76, F U. gingiva Bleeding
Ulceration
Bone exposure
Lung Stomach DLBCL + − 10 y − − + + +




− DLBCL + − 15 y − + + − −
16 Miyamoto et al25,a 72, F U. gingiva Pain
Ulceration
Bone exposure
− DLBCL + 0.5 y 8 y − + + − −
(Continues)
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antibiotic. Therefore, taking into consideration the com-
bination of ARONJ, orthopedic treatment with dermis de-
fect grafting and topical antibacterial drug delivery using 
a splint were actively performed in addition to antibiotic 
instillation, and the bone exposure improved, and the lesion 
healed.
Twenty-two cases of intraoral localized MTX-LPD with 
bone exposure have been reported, but only four cases had 
infection with purulent discharge.2,33,34 As bone expo-
sure because of LPD is caused by gingival necrosis due 
to lymphocyte infiltration, and infection is considered to 
be another pathology, there might be only four cases of 
true ARONJ complication where infection could not be 
controlled unless antibacterial drugs were used. Our case 
had severe infections repeatedly in a short time period; 
therefore, it was considered that LPD was complicated by 
ARONJ.
4 |  CONCLUSION
In cases with a history of oral MTX and presence of oral ul-
cers, it is important to perform biopsy and immunostaining 
for LPD-related markers, even if they meet the diagnostic cri-
teria for ARONJ. In addition, when bone exposure involves 
bacterial infection, aggressive antibiotic administration and 
surgical treatment are considered important to promote epi-
thelialization of the wound.
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